An interventional study of Prune in Bone Disease, Metabolic, sponsored by San Diego State University. Recruiting at 1 site in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2026-07-01.
Sponsored by San Diego State University · Not applicable, Interventional, and Prevention
Among 217 studies in Bone Diseases, Metabolic with a site in United States — 16 open to participants now, 21 under way, 1 of them phase 3. Bone Diseases, Metabolic · United States.
Among the 217 studies in Bone Diseases, Metabolic with a site in United States, this one is the 34th largest by planned enrollment of the 171 interventional ones that give a count, is one of 4 that started in 2024, is one of 57 with no phase, reaches primary completion later than 17 of the 20 other live ones, and was the 211th registered.
661 studies on the registry are indexed under Bone Diseases, Metabolic; 93 are open to participants now.
Browse Bone Diseases, Metabolic studies →16 of the 217 studies in Bone Diseases, Metabolic with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
Tufts Medical Center · Sites in United States
Ages 50+
AO Innovation Translation Center · Sites in United States, Australia, Brazil and 11 more countries
Ages 18+
Texas A&M University · Sites in United States
Ages 18–45 · Healthy volunteers
Wake Forest University Health Sciences · Sites in United States
Ages 60+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 63 Bone Diseases, Metabolic studies recruiting now, 27 (43%) set no upper age limit and 28 (44%) stop at 75 or younger; 12 take children under 18; 22 take healthy volunteers.
This study: female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
217 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 37 · Phase 3 39 · Phase 4 28
First in 1992; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 60 across 509 interventional studies indexed under Bone Diseases, Metabolic.
Median enrollment 66 across the 171 interventional studies, 61 across the 45 observational. Of the 180 that completed or were terminated, 82 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 217 have an industry lead sponsor. The 10 most frequent:
San Diego State University is the lead sponsor of 149 studies on the registry; 43 are open to participants now.
San Diego State University has 3 studies filed under Bone Diseases, Metabolic — fewer than ten, so there is no comparison to draw.
5 of the studies in Bone Diseases, Metabolic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04954664University of Alabama at BirminghamRidge Augmentation Using Allograft Particles Hydrated With or Without Recombinant Human Platelet-Derived Growth Factor | 2026-12 |
| NCT03374215National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks | 2026-12-31 |
| NCT05704036Johns Hopkins UniversityEstrogen Supplementation and Bone Health in Women With CF | 2027-01 |
| NCT05058976Susan L. GreenspanRomosozumab Use to Build Skeletal Integrity | 2027-03-31 |
| NCT07763509Cornell UniversityCalcium-Rich Food Versus Calcium Carbonate for Bone Health | 2027-06-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 217 studies in Bone Diseases, Metabolic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to examine if calcium and vitamin D supplements and/or prune can prevent bone loss in postmenopausal women.
Two hundred randomly assigned to one of two treatment groups: 1) 30 g prunes and 2) control (0 g prunes). Both groups received 500 mg calcium and 400 IU Vitamin D as a daily supplement. Blood samples are collected at baseline, 12 and 24 months to assess biomarkers of bone turnover. Physical activity recall and food records are obtained at baseline, 12 and 24 months to examine physical activity and dietary confounders as potential covariates. Dual-energy x-ray absorptiometry (DXA) and peripheral quantitative computed tomography (pQCT) will be completed at baseline, 12 and 24 months to examine bone mineral density and structure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants only receive 500 mg calcium and 400 IU vitamin D daily for 24 months.
Participants receive 500 mg calcium and 400 IU vitamin D daily for 24 months and 30 g of prune daily for 24 months.
Dietary Supplement: Prune
30 g of prune/day
Changes from baseline in bone mineral density at 12 and 24 months
bone mineral density as assessed by dual energy x-ray absorptiometry
Time frame: Baseline, 12 months, and 24 months
Changes from baseline in bone specific alkaline phosphatase at 12 months and 24 months
bone specific alkaline phosphatase (BAP) as assessed with ELISA
Time frame: Baseline, 12 months, and 24 months
Changes from baseline in tartrate acid phosphatase-5b at 12 months and 24 months
tartrate acid phosphatase-5b (TRAP5b) as assessed with ELISA
Time frame: Baseline, 12 months, and 24 months
Started Mar 2024 (actual). Primary completion is estimated for Dec 2028, 57 months after the start.
Of 161 non-industry interventional studies with no phase under Bone Diseases, Metabolic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 38. This study's planned 57 months is above that.
Counting every sponsor, half of 177 studies reached it within 22 months; a quarter within 10 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Prune